乐普生物创新药上市遇阻,合作方东曜药业“躺枪”

界面
04 Mar

界面新闻记者 |黄华界面新闻编辑 |谢欣3月4日晚,东曜药业官方公众号发文说明了客户乐普生物MRG003新药上市申请一事。简而言之便是,东曜药业紧急辟谣称,乐普生物主动撤回MRG003的新药上市申请(NDA),与其没有关系——与东曜药业所承担的相关工作完成情况及质量无关。乐普生物MRG003是一款EGFR靶向的ADC(抗体偶联药物)。今早,这款在研产品被曝上市遇阻。据中国国家药监局(NMPA)官网...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10